Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. Its point-of-care and lab-based products are accurate, effective and affordable, empowering healthcare practitioners to easily assess the risk of oral cancer early, and improve outcomes through earlier intervention. Vigilant Biosciences' OncAlert Oral Cancer Risk Assessment System™ point-of-care and lab assay products are currently undergoing the CE Mark registration approval process and not yet available for sale in any market at this time.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/25/15 | $5,500,000 | Series B |
Institute for Commercialization of Florida Technology venVelo White Owl Capital | undisclosed |
| 07/11/16 | $5,000,000 | Series B-2 |
venVelo White Owl Capital | undisclosed |
